Publications by authors named "Emi Nakatsugawa"
Article Synopsis
- The study investigates how plasma levels of the drug vonoprazan and its metabolic activity vary among patients with digestive disorders, aiming to identify factors influencing these variations.
- A total of 53 patients were analyzed, revealing significant individual differences in plasma vonoprazan levels, which were influenced by dosing and metabolic ratios.
- The findings suggest that while genetic variants in CYP3A5 and ABCB1 had no impact on plasma vonoprazan concentrations, CYP3A activity indicated by plasma 4β-OHC levels partially accounted for the observed variations.
Background/objectives: Clinical responses to naldemedine vary between individuals with advanced cancer. This is a prospective, single-center, observational study aimed to evaluate the influence of genetic polymorphisms and cachexia status on plasma naldemedine and clinical responses.
Methods: Forty-eight patients being treated with naldemedine for opioid-induced constipation under treatment of cancer pain were enrolled.
Background: Long-term use of itraconazole (ITZ) is associated with a risk of inducing hepatotoxicity. This study aimed to evaluate the associations of plasma concentrations of ITZ and its hydroxylated metabolite (OH-ITZ) with endogenous markers of hepatic function.
Methods: Thirty six patients treated with oral ITZ solution for prophylaxis of deep mycosis were enrolled.